Barclays
KRYS icon

Barclays’s Krystal Biotech KRYS Stock Holding History

Barclays’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$3.56M – 5108
2024
Q1 		$3.56M Buy
+20,000
New +$2.78M ﹤0.01% 2082

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Barclays's KRYS Position: Q2 2026 in Review

Barclays increased its Krystal Biotech (KRYS) stake by 50% in Q2 2026, buying an estimated $737K and bringing the position to 7,436 shares worth $2.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2179.

Barclays first reported a position in KRYS in Q4 2018 and has held it in 31 quarters since. The position peaked at $14.8M in Q4 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Barclays held 7,436 shares of Krystal Biotech worth $2.76M as of Q2 2026.
  • Barclays bought 2,467 Krystal Biotech shares in Q2 2026, an estimated $737K.
  • Krystal Biotech made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2179 holding.
  • Barclays first reported a position in Krystal Biotech in Q4 2018 and has held it in 31 quarters since.
  • Barclays's Krystal Biotech position peaked at $14.8M in Q4 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.